Someone posted a link to the full text. Looks like their main point is that for most people with diabetes (who have type 2), insulin of any form isn’t the best first line treatment, things like glp-1 receptor agonists (e.g., ozempic) work way better, but since it’s not “insulin” it’s not covered.
I’m guessing the editors of the Atlantic gave it the original bad headline, cause it seems like the author is genuine.
Still seems like an odd article choice since type 1 and 2 diabetes are totally separate diseases with different causes and treatments. So of course reducing insulin prices won’t do anything to help type 2 diabetics.
Someone posted a link to the full text. Looks like their main point is that for most people with diabetes (who have type 2), insulin of any form isn’t the best first line treatment, things like glp-1 receptor agonists (e.g., ozempic) work way better, but since it’s not “insulin” it’s not covered.
I’m guessing the editors of the Atlantic gave it the original bad headline, cause it seems like the author is genuine.
That makes more sense, I suppose.
Still seems like an odd article choice since type 1 and 2 diabetes are totally separate diseases with different causes and treatments. So of course reducing insulin prices won’t do anything to help type 2 diabetics.